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Abstract
Background: N-type Ca
2+ channels (Cav2.2) play an important role in the transmission of pain signals to the
central nervous system. ω-Conotoxin (CTx)-MVIIA, also called ziconotide (Prialt
®), effectively alleviates pain, without
causing addiction, by blocking the pores of these channels. Unfortunately, CTx-MVIIA has a narrow therapeutic
window and produces serious side effects due to the poor reversibility of its binding to the channel. It would thus
be desirable to identify new analgesic blockers with binding characteristics that lead to fewer adverse side effects.
Results: Here we identify a new CTx, FVIA, from the Korean Conus Fulmen and describe its effects on pain
responses and blood pressure. The inhibitory effect of CTx-FVIA on N-type Ca
2+ channel currents was dose-
dependent and similar to that of CTx-MVIIA. However, the two conopeptides exhibited markedly different degrees
of reversibility after block. CTx-FVIA effectively and dose-dependently reduced nociceptive behavior in the formalin
test and in neuropathic pain models, and reduced mechanical and thermal allodynia in the tail nerve injury rat
model. CTx-FVIA (10 ng) also showed significant analgesic effects on writhing in mouse neurotransmitter- and
cytokine-induced pain models, though it had no effect on acute thermal pain and interferon-g induced pain.
Interestingly, although both CTx-FVIA and CTx-MVIIA depressed arterial blood pressure immediately after
administration, pressure recovered faster and to a greater degree after CTx-FVIA administration.
Conclusions: The analgesic potency of CTx-FVIA and its greater reversibility could represent advantages over CTx-
MVIIA for the treatment of refractory pain and contribute to the design of an analgesic with high potency and low
side effects.
Background
Voltage-gated Ca
2+ channels (VGCC) play an important
role in the transmission of pain signals from peripheral
nerves to the brain [1-3]. Of several types of VGCC, the
N-type Ca
2+ channel is particularly important for percep-
tion of chronic nociceptive pain, as its blockade at the
spinal cord and sensory neurons inhibits stimulus-evoked
release of pain-inducing peptides, such as substance P,
and excitatory neurotransmitters, such as glutamate [4].
It is well known that various peptide toxins from animal
venom alleviate pain by specifically binding to N-type
Ca
2+ channels with high affinity [5]. For example, several
ω-conotoxins (CTxs), including GVIA, MVIIA, CVID
and SO-3, exert apparent analgesic effects against both
inflammatory and neuropathic pain [6-8].
Ziconotide (CTx-MVIIA; Prialt
®)i st h ef i r s tC T x -
derived drug to be approved for the treatment of refrac-
tory pain by the U.S. Food and Drug Administration
(FDA) [9]. Not only is ziconotide a highly potent analge-
sic, but it induces neither drug addiction nor tolerance,
as morphine does [10,11]. On the other hand, ziconotide
has both cardiovascular (tachycardia and orthostatic
hypotension) and nervous (confusion and dizziness) side
effects [12]. These effects are currently managed by
using a low initial dose that is then slowly titrated up in
the clinic [12-16]; nonetheless, the drug’s low clearance
rate from tissues limits the extent to which side effects
can be clinically managed [12,16]. A drug’sc l e a r a n c ein
vivo is closely related to its reversibility in vitro,w h i c h
makes reversibility an important factor in developing
analgesics targeting N-type Ca
2+ channels [17,18]. It was
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be applied in a clinical setting because of its near irre-
versibility, reflecting its slow onset and offset kinetics
[19]. It was also reported that CTx-CVID, a selective
and relatively reversible N-type Ca
2+ channel blocker,
has milder side effects than CTx-MVIIA [6,20,21].
In the present study, we report a new reversible CTx
identified from the Korean Conus Fulmen,w h i c hw e
named CTx-FVIA. CTx-FVIA shares 76% sequence
identity with CTx-MVIIA and 56% identity with CTx-
CVID (Figure 1). To investigate the potency and reversi-
bility of CTx-FVIA binding to N-type Ca
2+ channels, we
assessed its analgesic and blood pressure effects in
rodent models. Interestingly, CTx-FVIA showed a signif-
icantly higher degree of reversibility than CTx-MVIIA
following blockade of human N-type Ca
2+ channels,
despite their similar potencies. CTx-FVIA could thus
represent an improvement over ziconotide for treatment
of refractory neuropathic and inflammatory pain, and its
study could contribute to the design of even more effi-
cacious small-molecule analgesic agents with low side
effects.
Results
Cloning of CTx-FVIA
To clone CTxs from Conus Fulmen (Figure 1A), we
extracted the genomic DNA and conducted PCR using
forward and reverse primers that respectively corre-
sponded to the third intron and 3’UTR in the genomic
structure of the O-superfamily [22]. This strategy was
based on the fact that the O-superfamily consists of 4
exons and 3 introns, and the mature toxin is encoded in
the 4th exon. Using this process, we identified a novel
CTx, which we named CTx-FVIA, that is highly homolo-
gous with CTx-MVIIA, the major component of zicono-
tide (Prialt
®, ELAN Corp.) [16]. The cloned nucleotide
sequence is shown in Figure 1B. Sequence analysis
revealed a short mature region (78 bp) encoding a pep-
tide with a predicted size of 2566.99 Da. The residues
preceding the N-terminal end of the mature peptide
include basic amino acids (-XR), a putative proteolytic
cleavage site, and the C-terminal end of the mature
region, which is terminated with a cysteine residue that
is thought to be amidated by a monooxygenase [23].
A homology search revealed that CTx-FVIA has high
sequence similarity with CTxs SO3 (88%), MVIIA (76%),
CVIA (72%), CVID (56%) and GVIA (52%), which all
contain four loops separated by cysteine residues and
show structurally similar molecular topologies, together
with functionally important conserved residues (Tyr13,
Lys2, Arg10 and Arg21) [24].
Effects of CTx-FVIA and -MVIIA on human N-type
Ca
2+ channels
The inhibitory effects of CTx-FVIA and -MVIIA were
examined on human N-type Ca
2+ channels stably
expressed in HEK293 cells (C2D7 cells) [25]. Whole-cell
Ca
2+ channel currents were recorded using 5 mM Ba
2+
as the charge carrier. Ba
2+ currents were evoked by 200-
ms depolarizing voltage step commands from a holding
potential of -80 mV. The inward Ba
2+ current reached a
maximum amplitude with depolarization to 0 mV.
Figure 2A shows that bath applications of 100 nM CTx-
FVIA almost completely blocked the depolarization-acti-
v a t e di n w a r dB a
2+ current recorded from C2D7 cells.
This inhibitory effect of CTx-FVIA was dose-dependent
Figure 1 CTx-FVIA cloned from Conus Fulmen.( A )Conus Fulmen
lives in an area of subtropical sea south of Jeju island, South Korea.
This piscivorous snail captures its prey mainly by paralyzing it with a
mixture of toxins. (B) Nucleotide sequence and deduced amino acid
sequence of CTx-FVIA. Δindicates the position at which the carboxy
terminal of Arg is cleaved by conotoxin precursor proteases, and ▲
indicates the C-terminal cysteine that is thought to be amidated by
monooxygenase. The mature sequence of CTx-FVIA is underlined.
(C) Conotoxins homologous with CTx-FVIA are listed. Black box
indicates similarity of all the peptides; dark and light gray boxes
indicate similarity between five and four peptides, respectively. Six
cysteines form three disulfide bonds (1st-4th, 2nd-5th, 3rd-6th) and
four intercysteine loops.
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these CTxs, the inhibitory effect plateaued at a concen-
tration of 1 μM, and the IC50 values for CTx-FVIA and
-MVIIA were 11.5 ± 1.4 nM and 7.96 ± 1.6 nM, respec-
tively (Figure 2B). In other assays, CTx-FVIA had no
significant activities against other subtype of Ca
2+ chan-
nels (T-type and P/Q-type) and TTX-sensitive Na
+
channels of mouse DRG neuron (data not shown), simi-
lar with the previous results of homologous CTxs
[26-28].
Reversibility of the inhibitory effects of CTx-FVIA
Figure 2C shows that N-type Ca
2+ currents recorded
from C2D7 cells were almost completely blocked within
150-200 s after bath application of 100 nM CTx-FVIA
or -MVIIA, and that the currents recovered following
washout of the CTx. It is noteworthy, however, that
whereas CTx-FVIA and -MVIIA showed similar abilities
to block N-type Ca
2+ currents (91.25 ± 1.8% and 87.5 ±
1.9%, respectively, n = 5), the steady-state level to which
the currents recovered was lower after washout of CTx-
MVIIA (19.8 ± 3.8%) than after washout of CTx-FVIA
(78.4 ± 5.8%) (Figure 2C and 2D). In addition, kinetic
analyses revealed that the binding time constant (τon)
for CTx-MVIIA (211.4 ± 24.2 s) is much longer than
that for CTx-FVIA (56.3 ± 11.2 s) (Figure 2E).
The effect of CTx-FVIA in the formalin test
To compare the effects of CTx-FVIA and -MVIIA on
nociception, we first compared their effects in the for-
malin test, a mouse model of nociceptive pain. Subcuta-
neous injection of 5% formalin into the mouse hindpaw
produced acute nociceptive responses (i.e., licking, shak-
ing and biting) during the first 5 min (first phase) after
injection, as well as persistent nociceptive behavior
detected during a period extending from 20-40 min
after injection (second phase) [29]. Both CTx-FVIA and
-MVIIA significantly reduced the cumulative time of
intraplantar formalin-induced nociceptive behavior dur-
ing both phases. Interestingly, both toxins were more
effective during the second phase, which is closely
related to inflammatory pain and central sensitization
(Figure 3A) [30]. During the first phase, the ED50 values
for intrathecal CTx-FVIA and -MVIIA were 11.7 and
13.03 ng, respectively, and the corresponding ED50
values in the second phase were 6.31 and 6.41 ng,
respectively (Figure 3B). On the basis of the results sum-
marized in Figure 3, we suggest that the potencies of
Figure 2 Electrophysiological characteristics of CTx-FVIA and -MVIIA. (A) Representative traces of N-type Ca
2+ currents (control) in C2D7
cells showing blockade by 100 nM CTx-FVIA. (B) Concentration-response curves for CTx-FVIA and -MVIIA (n = 3). (C) Time-course of the block
induced by 100 nM CTx-FVIA or -MVIIV and its washout. Cells were held at -80 mV and depolarized to 0 mV. 100 nM CTx-FVIA (Δ) or CTx-MVIIA
(○) were applied until a complete block was achieved and then washed out. Currents were measured every 15 s. (D) Potency of CTx-FVIA and
-MVIIA and percent recovery after washout. (E) Averaged time constants τon for CTx-FVIA and -MVIIA determined from time-course graphs fitted
with a three-parameter single exponential function.
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acute and persistent formalin-induced nociception. We
therefore used both CTx-FVIA and -MVIIA at a dose of
10 ng for the following animal experiments.
The effect of CTx-FVIA on acute thermal pain
To test whether CTx-FVIA has an effect on acute ther-
mal pain, hot plate, plantar, and tail-flick tests were con-
ducted. For the hot plate test, mice were placed on a hot
plate at 54°C, and the time until they started licking or
lifting their hindpaws or jumping was recorded as an
indication of thermal pain. As shown in Figure 4A,
there was no significant difference in the latency before
paw withdrawal between mice administered intrathecal
10 ng of CTx-FVIA and those administered saline. Simi-
larly, CTx-FVIA showed no analgesic effect in the plan-
tar and tail-flick tests.
The effect of CTx-FVIA in the writhing test
Intraperitoneal administration of 1% acetic acid to mice
elicited a writhing response with an average score of
69.5 ± 1.9 (n = 11). Pretreatment with intrathecal 10 ng
of CTx-FVIA significantly reduced the number of
writhes to 36.4 ± 4.2 (n = 10). As a positive control,
intrathecal CTx-MVIIA similarly reduced the number of
writhes to 35.6 ± 6.1 (n = 11) (Figure 4B).
The effect of CTx-FVIA on neurotransmitter induced pain
Intrathecal injection of substance P (0.7 μg/5 μl) or glu-
tamate (20 μg/5 μl) produced an acute behavioral
response lasting about 30 min (Figure 4C). The intrathe-
cal administration of 10 ng of CTx-FVIA or -MVIIA
significantly reduced the cumulative duration of both
glutamate-induced and substance P-induced nociceptive
behavior, as compared to control (Figure 4C).
The effect of CTx-FVIA on cytokine-induced pain
Intrathecal injection of TNF-a (100 pg/5 μl), IL-1b (100
pg/5 μl) or IFN-g (100 pg/5 μl) also produced an acute
behavioral response lasting about 30 min (Figure 4D).
Mice pretreated with intrathecal 10 ng of CTx-FVIA or
-MVIIA showed significantly smaller pain responses to
TNF-a and IL-1b than the control group. Interestingly,
neither CTx-FVIA nor CTx-MVIIA had any effect on
nociceptive behavior induced by IFN-g (Figure 4D).
The effects of CTx-FVIA on mechanical and thermal
allodynia
We next investigated the effects of CTx-FVIA on
mechanical allodynia in the form of neuropathic pain
using an tail nerve injury (TNI) rat model in which the
left inferior caudal trunk was isolated, and the spinal
nerve between S1 and S2 was resected [31]. Two weeks
after the injury, the rats showed symptoms of neuro-
pathic pain, including mechanical, cold and warm allo-
dynia. The threshold for tail withdrawal in response to
stimulation with a von Frey filament was used to assess
mechanical allodynia. As shown in Figure 5A, the
threshold pressure for tail withdrawal was significantly
reduced from 14.1 ± 0.9 g (n = 7) to 0.6 ± 0.2 g (n = 7)
following the nerve injury. The effect of intrathecal
CTx-FVIA was dose-dependent (ED50 = 43.43 ng/kg),
and when rats administered a high dose (200 ng/kg), a
maximal increase in the pressure threshold (15 g, n = 7,
P < 0.001) was observed 15 min after injection, and the
Figure 3 Effects of intrathecal CTx-FVIA and -MVIIA on pain
responses induced by intraplantar (left hindpaw) formalin
injection. Mice were subcutaneously injected with formalin solution
(5%, 10 μl) 5 min after intrathecal administration of CTx-FVIA and
-MVIIA. (A) Effect of intrathecal CTx-FVIA and -MVIIA (32 ng) on the
cumulative time spent licking and biting the injected paw.
Measurements were made during the first phase (0-5 min) and
second phase (20-40 min) of the formalin response. There were 8-10
animals in each group. *P < 0.05, **P < 0.01, ***P < 0.005 vs.
control. (B) Dose-response curves for the indicated toxins during the
indicated period.
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FVIA exerts a potent analgesic effect against mechanical
allodynia.
To investigate the effects of CTx-FVIA on thermal
allodynia, we measured the latency of tail withdrawal in
response to stimulation with warm (40°C) or cold (4°C)
water. As shown in Figure 5B and 5C, TNI rats devel-
oped significant cold and warm allodynia; tail withdra-
wal latency was significantly reduced from 14.8 ± 0.2
sec (n = 7) to 8.3 ± 0.6 for cold allodynia and from 14.5
± 0.5 sec (n = 7) to 6.8 ± 1.2 for warm allodynia. One
hour after intrathecal administration of CTx-FVIA, tail
withdrawal latency had increased in both the cold and
warm thermal allodynia tests. It is noteworthy that
administration of a low dose (6.5 ng/kg) of CTx-FVIA
increased withdrawal latency only for cold allodynia,
suggesting CTx-FVIA is more effective against cold than
warm allodynia induced by tail nerve injury.
The effect of CTx-FVIA on blood pressure
N-type Ca
2+ channels are known to be distributed in
autonomic nerves, raising the possibility that intrave-
nous injection of CTx could have adverse effects on
cardiovascular function [32]. To compare the cardiovas-
cular effects of CTx-FVIA and -MVIIA, we initially
measured mean blood pressure in the femoral arteries
of rats. As shown in Figure 6A, intravenous administra-
tion of 100 μg/kg CTx-FVIA or -MVIIA reduced mean
arterial pressure to 56.4 ± 1.0 and 57.3 ± 3.1 mmHg,
respectively, within 3 min after injection. Blood pressure
then gradually recovered for the remainder of the 60-
m i no b s e r v a t i o np e r i o d .W i t h i n1 0m i n ,h o w e v e r ,t h e
recovery following CTx-FVIA injection was significantly
more pronounced than after CTx-MVIIA injection (P <
0.05), and after 60 min blood pressures had recovered
to 79.7 ± 4.1 and 65.3 ± 1.9 mmHg, respectively. In
order to resolve these effects over longer periods, blood
pressures were also measured using tail-cuff methods.
As shown in Figure 6B, 5 min after intravenous admin-
istration of CTx-FVIA, mean blood pressure had
declined significantly to 78.9 ± 3.1 mmHg from a base-
line of 97.8 ± 3.3 mmHg, but the pressure nearly recov-
ered within 5 h. By comparison, CTx-MVIIA similarly
lowered mean blood pressure to 77.5 ± 1.7 mmHg
within 5 min after drug injection, but then only recov-
ered to 87.4 ± 2.6 mmHg after 5 h (P < 0.05), reflecting
Figure 4 Effects of intrathecal CTx-FVIA and -MVIIA on acute and inflammatory pains. (A) Effects of CTx-FVIA on acute pain responses.
CTx-FVIA (10 ng) was administered intrathecally 5 min before the indicated tests. There were 7-10 animals in each group. (B-D) Effects of CTx-
FVIA and -MVIIA on pain responses elicited by acetic acid (intraperitoneal), substance P, glutamate, TNF-a, IL-1b and IFN-g (intrathecal). These
agents were applied 5 min after 10 ng CTx-FVIA or -MVIIA was administered intrathecally. Pain responses, including writhing, licking, biting and
scratching, were measured for 30 min after injection. (B) Acetic acid-induced writhing counts. (C) Cumulative duration of neurotransmitter-
evoked pain behavior. (D) Cumulative duration of inflammatory cytokine-evoked pain behavior. The data are presented as means ± SEM. There
were 9-13 animals in each group. Con (control) refers to the saline-treated group. *P < 0.05, **P < 0.01, ***P < 0.005 vs. control.
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2+ channel block
b yC T x - M V I I A .T h u sC T x - F V I Aa p p e a r st oe x e r t
milder cardiovascular side effects than CTx-MVIIA.
Discussion
Highly reversible CTx-FVIA
Cone snails, a venomous marine gastropod, uses peptide
toxins (conotoxins) to capture prey and protect them-
selves [33]. It is estimated that approximately 500 spe-
cies of cone snail each express 50-200 conotoxins with
little overlap, thereby making up a library of >50,000
peptides. These toxins, which are usually characterized
through gene cloning or biochemical purification, are
highly useful in neuropharmacology, thanks to the speci-
ficity with which they bind to various ion channel sub-
types [34]. CTx-MVIIA was biochemically purified from
the venom of Conus Magus [35] and was recently
approved by the U.S. FDA as an analgesic for the treat-
ment refractory pain [9,11]. Unfortunately, side effects
due to the poor reversibility of CTx-MVIIA narrow its
therapeutic window. Given the extreme diversity of the
CTx library, we endeavored to overcome the limitations
of CTx-MVIIA by identifying a CTx with more favor-
able characteristics. CTx-FVIA was isolated through
gene cloning from Conus Fulmen. As expected from its
homology, the potencies and selectivity of CTx-FVIA
and -MVIIA were similar, as judged from their effects
on evoked N-type Ca
2+ currents (Figure 2B) and other
Ca
2+ and Na
+ currents. Interestingly, however, following
blockade by CTx-FVIA, currents showed significantly
greater recovery than after blockade by CTx-MVIIA.
Although our observation of the poor reversibility of
CTx-MVIIA is at variance with some other reports
[20,26,36], clinical observations support our finding that
CTx-MVIIA is poorly reversible [12]. Our assay system
may reflect the clinical results because C2D7 cells may
mimic human neuropathic or inflammatory pain states
by overexpressing the a2bδ subunits of the N-type Ca
2+
channel [25], which are up-regulated by neuropathic
pain, and by modulating the a1B subunit [37,38]. In
addition, comparison of their τon kinetic constant sug-
gests CTx-FVIA binds to the channels more rapidly
than CTx-MVIIA (Figure 2E). We would also expect
that CTx-FVIA dissociates from channels faster than
CTx-MVIIA because the two toxins have similar IC50
values (apparent Kd =K off/Kon). Several factors report-
edly affect the binding kinetics and reversibility of cono-
toxins. These include the holding potential (Vh), the
divalent cation concentration, the presence of the a2δ
auxiliary subunit, and mutation of channel protein resi-
dues (Gly1326) or CTx residues (Arg10) [20,36,39-41].
Given that these factors were identical for each CTx in
Figure 5 Analgesic effects of intrathecal CTx-FVIA on
neuropathic pain. (A-C) Time-course of antinociceptive effects of
intrathecal CTx-FVIA (6.5, 20, 65 and 200 ng/kg) on allodynia in an
TNI rat model: (A) mechanical allodynia; (B) cold allodynia; and (C)
warm allodynia. The data are presented as means ± SEM. There
were 5-8 animals in each group. *P < 0.05, **P < 0.01, ***P < 0.001
vs. the saline group (two-way ANOVA followed by Bonferroni’s
tests).
Lee et al. Molecular Pain 2010, 6:97
http://www.molecularpain.com/content/6/1/97
Page 6 of 12our setting, it seems that other factors, perhaps related
to the six residues that differ between their sequences,
control the binding kinetics and reversibility CTx-FVIA
and -MVIIA. It would be interesting to undertake muta-
genesis studies to explore how these localized differ-
ences influence the binding kinetics of these two toxins.
The fast kinetics and relatively high reversibility of CTx-
FVIA could be of clinical importance, as its greater
reversibility could reduce its toxicity and facilitate man-
agement of its side effects [17,18].
Analgesic effects of CTx-FVIA
The potency with which CTx-FVIA blocks N-type Ca
2+
channels and its homology with CTx-MVIIA suggests
CTx-FVIA should be effective against pain in vivo.T o
test this hypothesis, we used several rodent pain models.
Pain is classified as acute pain, which is essential for
survival of the organism, and persistent pain, which is
pathological and often accompanied by a lowered pain
threshold. The formalin test is useful to investigate drug
effects on both acute and persistent pain because it pro-
duces two phases of nociceptive behavior. First phase
pain is caused by direct effects on nociceptors leading to
activation of primary afferent fibers, but second phase
pain is caused by tonic inflammatory nociceptive
responses. The effects of CTx-FVIA and -MVIIA were
more pronounced during the second phase than during
the first, indicating that CTxs reduce pathological pain
more effectively than acute pain (Figure 3). When an
effective dose (10 ng) of CTx-FVIA was intrathecally
administered in acute thermal pain models (hot plate or
tail-flick), the latency times were little affected or per-
haps even reduced (plantar test) (Figure 4A). By con-
trast, CTx-FVIA effectively reduced thermal allodynia
caused by peripheral nerve injury (Figure 5B and 5C).
These findings are similar to results previously reported
for CTx-MVIIA in tail-flick or formalin tests [6,8,42]
and suggest that N-type Ca
2+ channel blockers are more
effective against chronic pain than acute pain. This may
be due in part the fact that expression of N-type Ca
2+
channels is up-regulated by chronic pain, reflecting the
plasticity of the affected synapses [37,38,43,44].
Chronic pain is further divided into inflammatory pain
and neuropathic pain, based on the underlying mechan-
ism [43]. Inflammatory pain is caused by the actions of
various inflammatory mediators, including cytokines,
growth factors, neurotransmitters and protons, while
neuropathic pain is caused by nervous system dysfunc-
tion and is well characterized in rodents with respect to
the location and form of the nerve injury involved
[45,46]. In the present study, intraperitoneal injection of
acetic acid or intrathecal injection of glutamate, sub-
stance P, TNF-a,I L - 1 b or IFN-g were used to simulate
inflammatory pain [47]. Intraperitoneal injection of
acetic acid is considered to be a model of visceral
inflammatory pain, while neurotransmitters and pro-
inflammatory cytokines play important roles in the
development of inflammatory pain in the spinal cord,
where they produce pain signals by directly activating
nociceptors or by sensitizing the peripheral nervous sys-
tem [43]. At effective doses (e.g., 10 ng), CTx-FVIA and
-MVIIA exerted analgesic effects in all of these inflam-
matory pain models, with the exception of IFN-g-
induced pain (Figure 3 and 4), which suggests the invol-
vement of N-type Ca
2+ channels in the pain pathway
activated by these inflammatory mediators. The ways in
which inflammatory mediators increase pain sensitiza-
tion through ion channel modulation have been
Figure 6 Effects of intravenous CTx-FVIA and -MVIIA on blood
pressure. (A) Effects of intravenous CTx-FVIA and -MVIIA (100 μg/
kg) on mean arterial pressure measured in the femoral artery of
anaesthetized rats and (B) on mean blood pressure measured using
the tail-cuff method. The data are presented as means ± SEM. *P <
0.01 vs. the pre-dosing value (repeated measures ANOVA followed
by Dunnett’s test). #P < 0.05 CTx-FVIA vs. CTx-MVIIA (10 min to 60
min, repeated measures ANOVA).
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pain in the formalin test is related to an inflammatory
reaction in peripheral tissues [30] and requires nocicep-
tive neurotransmitter release and activation of postsy-
naptic N-methyl-D-aspartate (NMDA) receptors [48].
Intrathecal neurotransmitters and pro-inflammatory
cytokines also induce inflammatory pain by modulating
ion channels [49-51]. In particular, TNF-a and IL-1b
increase tetrodotoxin-resistant Na
+ channel currents
and sensitize N-type Ca
2+ channels [52,53]. It is note-
worthy that CTx-FVIA and -MVIIA do not reduce IFN-
g induced pain, although they effectively alleviate pain
induced by acetic acid, substance P, glutamate, TNF-a
or IL-1b (Figure 4B, C and 4D). It may be that different
nociceptive stimuli use different pain pathways or mod-
ulate different channels [43,54]. It is not well understood
how substance P, glutamate and IL-1b affect N-type Ca
2
+ channels, but our results suggest they at least evoke
pain signals via N-type Ca
2+ channels, probably situated
postsynaptically. In two neuropathic pain models, SNL
(data not shown) and TNI, CTx-FVIA also exerted
dose- and time-dependent anti-allodynic effects
( F i g u r e5 ) .T h e s ee f f e c t so fN - t y p eC a
2+ channel block-
ers have been observed in several neuropathic pain
models [6,55,56], and our results showing that CTx-
FVIA is effective against neuropathic pain developed by
S1/S2 nerve injury are similar. Taken together, our
results indicate that the CTx-FVIA is as effective an
analgesic as CTx-MVIIA in inflammatory and neuro-
pathic pain models, and establishes that the residues
essential for blocking N-type Ca
2+ channels are effective
on a scaffold of CTx-FVIA (Figure 1C) [24,57-59].
In vivo reversibility of CTx-FVIA
N-type Ca
2+ channels are widely expressed in autonomic
nerves innervating the blood vessels, as well as presy-
naptic nerves in the spinal cord and brain [32,60]. Acti-
vation of N-type Ca
2+ channels in sympathetic nerves
leads to release of norepinephrine, thereby increasing
blood pressure. Consequently, the cardiovascular side
effects of CTxs would be expected to reflect inhibition
of norepinephrine release. For example, intravenous
injection of CTx-GVIA, -MVIIA or -CVID induces
hypotension and reflex tachycardia [60]. To assess the
cardiovascular effects of CTx-FVIA and -MVIIA, we
measured their effects on mean arterial blood pressure
w i t had o s eo f1 0 0μg/kg. The CTx dose (100 μg/kg) is
very high. To visualize a recovery pattern with reversible
effects, however, we used a high dosage of the toxin
(100 μg/kg). When a relatively low CTx dose (10 μg/kg)
was intravenously administered into rats, in fact, we
could not observe any apparent difference between
CTx-FVIA and CTx-MVIIA in recovery pattern
of blood pressure. Similarly it was reported that Wright
et al. used a high dose of toxin (100 μg/kg) in an
experiment for cardiovascular and autonomic effects
[60]. As with its effect on N-type Ca
2+ currents, the
effect of CTx-FVIA on blood pressure was more reversi-
ble than that of CTx-MVIIA (Figure 2C and Figure 6).
Although slow reversibility could be an advantage, in
that it could prolong the therapeutic effects of CTx-
MVIIA, it also makes management of the side effects
caused by prolonged N-type Ca
2+ channel blockade
difficult. Consequently the greater reversibility of CTx-
FVIA could be advantageous for its clinical application
in the treatment of pathological pain [17,18,61].
Conclusions
Collectively then, our findings suggest that CTx-FVIA
could represent an improvement over CTx-MVIIA for
treatment of refractory neuropathic and inflammatory
pain. Additional study will be required to fully under-
stand the factors contributing to the reversibility of
CTx-FVIA, which we would expect to facilitate improve-
ment in the clinical applicability and efficacy of this
class of drugs.
Methods
Cloning of CTx-FVIA
Specimens of Conus Fulmen were collected from an area
of subtropical sea south of Jeju island, Republic of
Korea. Frozen hepatic tissue (0.1 g) from Conus Fulmen
was added to 1 ml of GES reagent (5 M guanidinium
thiocyanate, 100 mM EDTA, 0.5% v/v Sarkosyl) and
then ground with a glass homogenizer [62]. After centri-
fugation, the supernatant was mixed with phenol and
chloroform and centrifuged again at room temperature.
The colorless upper aqueous phase was then transferred
to a fresh tube and mixed with 1 ml of isopropanol to
precipitate the genomic DNA. The resultant pellet was
w a s h e dt w i c ei n7 0 %e t h a n o la n dd i s s o l v e di n5 0μlo f
10 mM Tris-HCl (pH 8.5). The collected genomic DNA
was used as a template for PCR with a forward primer
(5’-CTCTCTCTCTCTCTGCTGGAC-3’) and reverse
primer (5’-CAGAAAAGGATAGAGCACAGAAGG-3’)
corresponding respectively to the third intron and 3’
UTR in the genomic structure of the O-superfamily.
The PCR protocol entailed 35 cycles of 94°C for 30 s,
55°C for 30 s and 70°C for 45 s. The purified PCR pro-
ducts were ligated into pGEM-Teasy vector (Promega)
and then transformed to competent DH5a cells. The
nucleic acid sequences of the expressed clones were
determined using an ABI Prism 3700 DNA analyzer
(Figure 1B).
Peptide synthesis
The sequences of CTx-FVIA and CTx-MVIIA are
shown in Figure 1C. The linear precursors of each
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with Fmoc chemistry, starting from Rink-amide resin.
Briefly, synthetic peptides were deprotected and cleaved
using a mixture containing 82.5% TFA, 2.5% 1,2-ethane-
dithiol, 5% H2O, 5% thioanisole and 5% phenol (v/v).
Each linear peptide was diluted to a final concentration
of 2.5 × 10
-5 M and subjected to oxidative disulfide
bond formation for 3 days at 4°C in 0.3 M ammonium
acetate buffer (pH 7.8) containing 0.5 M guanidine
hydrochloride and reduced/oxidized glutathione (pep-
tide:GSH:GSSG molar ratio was 1:100:10). Preparative
RP-HPLC was performed using a Shimadzu LC-6AD
system with an ODS column (20 × 250 mm). The purity
of the synthetic peptides was confirmed by analytical
RP-HPLC and MALDI-TOF mass spectrometry.
Electrophysiological measurements
C2D7 cells expressing the a1B-1, a2bδ,a n db1b subunits
of N-type Ca
2+ channels were cultured in DMEM med-
ium supplemented with 1% penicillin/streptomycin, 5%
bovine calf serum, 0.5 g/L geneticin and 30 U/ml hygro-
mycin [25]. Total Ba
2+ currents were measured using
the whole-cell patch clamp technique. Coverslips with
cells were mounted in a perfusion chamber and con-
stantly perfused using a gravity feed system with a mod-
ified HEPES-balanced external solution (151 mM
tetraethylammonium chloride, 10 mM HEPES, 5 mM
BaCl2,1m MM g C l 2,a n d1 0m Mg l u c o s e ;p Hw a s
adjusted to 7.4 and osmolarity to 310 mOsm) to isolate
the Ba
2+ currents. Electrodes were made of borosilicate
glass and had a resistance of 3-4 MΩ when filled with
pipette solution. The pipette solution contained 100
mM CsCl, 1 mM MgCl2, 10 mM HEPES, 10 mM
B A P T A ,3 . 6m MM g A T P ,1 4m Mp h o s p h o c r e a t i n e
(CrP), 0.1 mM LiGTP and 50 U/ml creatine phosphoki-
nase (CrPK). The solution pH was adjusted to 7.2 using
CsOH. Ba
2+ currents were recorded using an EPC-9
amplifier, and the data were analyzed using Pulse/Pulse-
fit (HEKA, Germany) and GraphPad Prism (GraphPad
Inc.) software.
Drugs and animals
Formalin, acetic acid, substance P and glutamate were
p u r c h a s e df r o mS i g m aC h e m i c a lC o .( S t .L o u i s ,M O ) .
TNF-a,I F N - g and IL-1b were from R and D Systems
Inc. (Minneapolis, MN, USA). All drugs were prepared
just before use in 0.9% NaCl (w/v). Adult male Sprague-
Dawley rats weighing 150-200 g or ICR mice weighing
23-25 g were used. Animals were housed together in
groups in a room maintained at 22 ± 0.5°C and had
unrestricted access to food and water. The animals were
allowed to adapt to the experimental conditions in the
laboratory for at least 2 h before pain testing. All proce-
dures were conducted in accordance with the Guide for
Care and Use of Laboratory Animals published by the
U.S. National Institutes of Health and the ethical guide-
lines of the International Association for the Study of
Pain.
Intrathecal and intravenous injection of CTx-FVIA and
CTx-MVIIA
Using the method of Hylden and Wilcox [63,64], con-
scious mice or enflurane-anesthetized rats were intrathe-
cally injected using a 30-gauge needle connected to a
25-μl Hamilton syringe via polyethylene tubing. The
injected volume was 5 μl, and the injection site was veri-
fied by injecting a similar volume of 1% methylene blue
solution and determining the distribution of the dye in
the spinal cord. The injected dye was distributed both
r o s t r a l l ya n dc a u d a l l yb u td i f f u s e do n l yas h o r td i s t a n c e
(about 0.5 cm), and no dye was found in the brain.
Before any experiments were done, the success rate for
intrathecal injections was consistently >95%. Intravenous
injections were made into the lateral tail vein of con-
scious rats using a 26-gauge needle connected to 1 ml
syringe.
Formalin test
Formalin tests were carried out as previously described
by Hunskaar et al. [29]. Briefly, mice were intrathecally
injected with 3.2, 10, 32, or 100 ng/5 μl of CTx-FVIA or
CTx-MVIIA, or physiological saline (control) 5 min
before formalin testing. Thereafter, 10 μl of 5% formalin
in saline (0.9% NaCl) were subcutaneously injected into
the plantar surface of the left hindpaw, and the elicited
behaviors, including licking, biting, scratching or shak-
ing, were recorded and counted. Throughout this
experiment the mice were observed in a transparent
observation chamber (acrylic-plastic, 20 × 20 cm in dia-
meter × height), and the counts were divided into two
phases. The first phase extended from 0-5 min after
injection, while the second phase extended from 20-40
min after injection. The total observation period was 40
min.
Acute thermal pain tests
Mice were intrathecally injected with 5 μl of CTx-FVIA
(0.01 μg/5 μl) or physiological saline (control) 5 min
before testing. The tail-flick test was then performed
using a commercially available apparatus (Model TF6,
EMDIE Instrument Co.). The body of each mouse was
held with a hand, and their tail was extended so that the
distal part could be irradiated with light at an intensity
of 3.8 mWatt/cm
2 to impose a heat stimulus. The time
it took the mouse to flick its tail was then recorded with
a cut-off time of 10 sec. Plantar test of pain threshold
was also performed using a commercially available appa-
ratus (Plantar test 7371, Ugo Basile). In this case, each
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the plantar pad of one paw with light at an intensity of
90 mWatt/cm
2, and the latency of paw withdrawal was
measured with a cut-off time of 15 sec. For the hot-
plate test, mice were individually placed on a hot plate
(54°C) and the reaction time, from placement of the
mouse on the hot plate to the time the mouse began
licking a front-paw was measured with a cut-off time of
30 sec. The dimensions of the hot plate apparatus were
30 × 30 × 30 cm (Model 39 Hot Plate, Itic Life Science).
Writhing test
Mice were intrathecally injected with 0.01 μg/5 μlo f
CTx-FVIA, -MVIIA, or physiological saline (control) 5
min before testing. For the writhing test, mice were
intraperitoneally injected with 0.5 ml of 1% acetic acid
in saline. The number of writhes was counted during a
30 min period following the injection. A writhe was
defined as a contraction of the abdominal muscles
accompanied by an extension of the forelimbs and elon-
gation of the body.
Nociceptive behavior induced by substance P, glutamate
or inflammatory cytokines
Mice were intrathecally injected with 0.01 μg/5 μlo f
CTx-FVIA, -MVIIA, or physiological saline (control) 5
min before testing. Thereafter, mice were intrathecally
injected with 0.7 μg/5 μl of substance P, 20 μg/5 μlo f
glutamate or 100 pg/5 μlo fT N F - a,I F N - g or IL-1b and
then immediately placed in an observation chamber
(described above). The durations of the pain-like
responses, which included licking, biting and scratching
the abdomen and hind regions of the body, were
recorded for 30 min. The cumulative durations of the
pain-like responses were measured using a stopwatch.
These characteristic behaviors induced by the pharma-
cological effects of the injected agents were not observed
in the vehicle-treated control group.
Tail nerve injury (TNI) rat models
Under enflurane anesthesia, the left superior and infer-
ior caudal trunks were isolated and resected between
the S1 and S2 spinal nerves [31,65]. To prevent possible
rejoining of the proximal and distal ends of the severed
trunk, a piece of the trunk (about 1-2 mm) was removed
from the proximal end. Two weeks after surgical proce-
dure, the mechanical sensitivity of the tail was measured
based on the frequency of tail flicks induced by applica-
tion of different von Frey filaments. Each rat was placed
in a transparent plastic tube, 5.5 × 15 cm or 6.5 × 18
cm (diameter × length), depending on their body size;
the tube had to be small enough to prevent the rat from
turning around. For testing, a series of eight von Frey
filaments (0.41, 0.70, 1.20, 2.00, 3.63, 5.50, 8.50 and
15.14 g) were used after calibration. The von Frey
filaments were applied to the tails, starting with a fila-
ment of 2.00 g; initially the most sensitive area was
determined by rubbing various areas of the tail with the
shank of the von Frey hair, and then, this area was chal-
lenged systematically by applying static pressure with
the von Frey hair to locate the spot. An abrupt tail
movement of about 0.5-20 cm in response to von Frey
hair stimulation is considered to be an abnormal
response, indicative of mechanical allodynia. During
repeated trials, the test stimuli can be easily delivered to
the same spot without difficulty, since the tail is usually
stationary. Rats were intrathecally injected with 6.5, 20,
65, or 200 ng/kg of CTx-FVIA, or physiological saline
(control). The 50% withdrawal threshold was determined
using the up-down method described by Chaplan et al.
[66].
Thermal sensitivity was assessed by immersing the tail
in cold (4°C) or warm (40°C) water. Following tail
immersion, the investigator observed the tail to see if it
moved abruptly, as in the tail-flick test, and measured
the latency of the tail response with a cut-off time of
15 s. The tail immersion test was repeated five times at
5 min intervals to obtain the average tail response
latency for each animal on each experimental day.
Mean arterial pressure test
A l ls u r g i c a lp r o c e d u r e sw e r e performed using aseptic
technique. A polyethylene-10 catheter was inserted into
the femoral artery of Sprague-Dawley rats to record
invasive arterial blood pressure (IntelliVue MP30, Phi-
lips). Catheterization and all of the measurement for
blood pressure were done under general anesthesia with
isoflurane. After taking the basal level of mean arterial
pressure, 100 μg/kg of CTx-FVIA or -MVIIA was
injected intravenously, and mean arterial pressure was
measured over time.
Longer-term monitoring of blood pressure using a tail-
cuff
Twenty Sprague-Dawley rats were randomly divided into
two groups receiving CTx-FVIA (100 μg/kg) or CTx-
MVIIA (100 μg/kg). Each group included 10 rats, and
drugs were administered by intravenous injection. The
systolic and diastolic blood pressures were measured
before and 5 min, 3 h, 5 h and 24 h after drug adminis-
tration using the tail-cuff method [67].
Statistical analysis
Data are presented as means ± SEM, and ED50 values
are reported as geometric means accompanied by their
respective 95% confidence limits. The statistical signifi-
cance of differences between groups was assessed with
t-tests (and nonparametric tests) or with one-way or
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Bonferroni’s or Dunnett’s post-hoc test. All tests were
performed using GraphPad Prism version 4.0 for Win-
dows. Values of P < 0.05 were considered significant.
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